August 5, 2013 — Surgery is not always necessary for women with a type of breast tissue abnormality associated with a higher risk of cancer, according to a new study published online in the journal Radiology. Researchers said that periodic imaging and clinical exams are effective in these patients when radiology and pathology findings are benign and concordant, or in agreement.

Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) are abnormal breast lesions that occasionally appear as incidental findings in breast biopsies. Women with ALH or LCIS have a four to 10 times higher risk of developing breast cancer, according to Michael A. Cohen, M.D., FACR, professor of radiology at the Emory University School of Medicine in Atlanta. As a result, it is often recommended that ALH and LCIS diagnosed on image-guided core biopsy be removed surgically. “Because of the possibility of upgrade to cancer, the bulk of the published literature says that the prudent thing to do is excise ALH and LCIS,” Cohen said.

But new research from Cohen, Kristen Atkins, M.D., and colleagues may alter that thinking. Atkins is a pathologist and associate professor at the University of Virginia in Charlottesville. At one time, Cohen and Atkins were colleagues there and had many discussions about balancing the risk of cancer in ALH and LCIS patients with the costs and potential complications of surgery.

“From a pathology perspective, ALH and LCIS are often very tiny lesions, so we wondered why they were getting excised,” Atkins said. “These surgeries may involve general anesthesia and possible disfigurement.”

The researchers studied 10 years of pathology and radiology data to look for a correlation between the number of ALH and LCIS cases that were upgraded to cancer after surgery or follow-up and the concordance between the radiologist and pathologist. The research yielded 50 cases from 49 women aged 40 to 73 years. Radiologist and pathologist findings were concordant in 43 of the 50 cases. None of the benign concordant cases were subsequently upgraded to cancer, strongly suggesting that observation in these patients would have been a viable alternative to surgery. Of the seven discordant cases, two were upgraded to ductal carcinoma in situ (DCIS) an early-stage, noninvasive form of breast cancer.

Cohen repeated the study after moving to Emory and found the same results. “When there’s no discordance between the radiologist and pathologist after thorough radiology-pathology correlation, there’s no upgrade from ALH or LCIS to cancer in our study,” Cohen said. “These findings show that some women can avoid surgery, and that yearly mammograms along with MRI [magnetic resonance imaging] or ultrasound as second-line screening tools may suffice.”

The researchers suggested their findings will help physicians and patients make informed decisions about ALH and LCIS.

For more information: http://radiology.rsna.org


Related Content

News | Breast Imaging | Washington University

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or ...

Time January 29, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Mammography

Jan. 16, 2026 — Vega Imaging Informatics has announced the successful curation of the world’s largest digital breast ...

Time January 19, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — VizMark has received U.S. Food and Drug Administration FDA 510k clearance for VM1, a non-metal visual ...

Time January 19, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — Susan G. Komen, the world’s leading breast cancer organization commends Assemblymember Lori Wilson (D ...

Time January 16, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — iSono Health has announced the commercial launch of ATUSA, an FDA-cleared, wearable and automated 3D ...

Time January 14, 2026
arrow
News | Women's Health

Dec. 12. 2025 — A new study has found that an individualized approach to breast cancer screening that assesses patients’ ...

Time December 17, 2025
arrow
News | Breast Imaging

Dec. 16, 2025 — Hologic, Inc, a medical technology company dedicated to improving women’s health, recently announced new ...

Time December 16, 2025
arrow
News | FDA

Dec. 8, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, has submitted a 510(k) premarket ...

Time December 08, 2025
arrow
News | Breast Imaging

Dec. 01, 2025 — DeepHealth, a wholly owned subsidiary of RadNet, Inc., has launched the DeepHealth Breast Suite,2 an end ...

Time December 04, 2025
arrow
Subscribe Now